Search

Your search keyword '"J. Tatzelt"' showing total 104 results

Search Constraints

Start Over You searched for: Author "J. Tatzelt" Remove constraint Author: "J. Tatzelt"
104 results on '"J. Tatzelt"'

Search Results

2. Recombination between adenovirus type 12 DNA and a hamster preinsertion sequence in a cell-free system. Patch homologies and fractionation of nuclear extracts

3. Topological confinement by a membrane anchor suppresses phase separation into protein aggregates: Implications for prion diseases.

4. Regulated Proteolysis Induces Aberrant Phase Transition of Biomolecular Condensates into Aggregates: A Protective Role for the Chaperone Clusterin.

5. Cleavage site-directed antibodies reveal the prion protein in humans is shed by ADAM10 at Y226 and associates with misfolded protein deposits in neurodegenerative diseases.

6. Liquid-liquid phase separation of the prion protein is regulated by the octarepeat domain independently of histidines and copper.

7. Morphological Transformations of SARS-CoV-2 Nucleocapsid Protein Biocondensates Mediated by Antimicrobial Peptides.

8. VCP/p97 mediates nuclear targeting of non-ER-imported prion protein to maintain proteostasis.

9. Cross-seeding by prion protein inactivates TDP-43.

10. NEMO reshapes the α-Synuclein aggregate interface and acts as an autophagy adapter by co-condensation with p62.

11. Hydration makes a difference! How to tune protein complexes between liquid-liquid and liquid-solid phase separation.

12. Linear ubiquitination induces NEMO phase separation to activate NF-κB signaling.

13. LUBAC assembles a ubiquitin signaling platform at mitochondria for signal amplification and transport of NF-κB to the nucleus.

14. Bivalent metal ions induce formation of α-synuclein fibril polymorphs with different cytotoxicities.

15. Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies.

16. Remodeling of the Fibrillation Pathway of α-Synuclein by Interaction with Antimicrobial Peptide LL-III.

17. Biological Functions of the Intrinsically Disordered N-Terminal Domain of the Prion Protein: A Possible Role of Liquid-Liquid Phase Separation.

18. The N-terminal domain of the prion protein is required and sufficient for liquid-liquid phase separation: A crucial role of the Aβ-binding domain.

19. The key role of solvent in condensation: Mapping water in liquid-liquid phase-separated FUS.

20. The G127V variant of the prion protein interferes with dimer formation in vitro but not in cellulo.

21. SecY-mediated quality control prevents the translocation of non-gated porins.

22. Transgenic Overexpression of the Disordered Prion Protein N1 Fragment in Mice Does Not Protect Against Neurodegenerative Diseases Due to Impaired ER Translocation.

23. The parkin-coregulated gene product PACRG promotes TNF signaling by stabilizing LUBAC.

24. The prion protein in neuroimmune crosstalk.

25. A protein quality control pathway regulated by linear ubiquitination.

26. The signal peptide plus a cluster of positive charges in prion protein dictate chaperone-mediated Sec61 channel gating.

27. GPI-anchor signal sequence influences PrPC sorting, shedding and signalling, and impacts on different pathomechanistic aspects of prion disease in mice.

28. Dimerization of the cellular prion protein inhibits propagation of scrapie prions.

29. Alterations in the brain interactome of the intrinsically disordered N-terminal domain of the cellular prion protein (PrPC) in Alzheimer's disease.

30. Structural and mechanistic aspects influencing the ADAM10-mediated shedding of the prion protein.

31. Impaired transport of intrinsically disordered proteins through the Sec61 and SecY translocon; implications for prion diseases.

32. The Sec61/SecY complex is inherently deficient in translocating intrinsically disordered proteins.

33. Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice.

34. The N-terminus of the prion protein is a toxic effector regulated by the C-terminus.

35. The RAB GTPase RAB18 modulates macroautophagy and proteostasis.

36. Secretory pathway retention of mutant prion protein induces p38-MAPK activation and lethal disease in mice.

37. Cytoplasmic protein aggregates interfere with nucleocytoplasmic transport of protein and RNA.

38. The Cellular Prion Protein: A Player in Immunological Quiescence.

39. Parkin cooperates with GDNF/RET signaling to prevent dopaminergic neuron degeneration.

40. The α-helical structure of prodomains promotes translocation of intrinsically disordered neuropeptide hormones into the endoplasmic reticulum.

41. Nanomedicine for prion disease treatment: new insights into the role of dendrimers.

42. Prion disease: a tale of folds and strains.

43. Structural features within the nascent chain regulate alternative targeting of secretory proteins to mitochondria.

44. The E3 ligase parkin maintains mitochondrial integrity by increasing linear ubiquitination of NEMO.

45. Anti-prion drug mPPIg5 inhibits PrP(C) conversion to PrP(Sc).

46. The heat shock response is modulated by and interferes with toxic effects of scrapie prion protein and amyloid β.

47. Different effects of Sec61α, Sec62 and Sec63 depletion on transport of polypeptides into the endoplasmic reticulum of mammalian cells.

48. Cellular prion protein mediates toxic signaling of amyloid beta.

49. The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.

50. Parkin is transcriptionally regulated by ATF4: evidence for an interconnection between mitochondrial stress and ER stress.

Catalog

Books, media, physical & digital resources